NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ghosh et al. (2012) have shown in gene expression analysis that leukemic cells from AML, ALL or CML patients display reduced levels of IL-6, a target gene of the transcription factor NFkB, when treated with the telomerase inhibitor MST-312.